Skip to Main Content

Paper Details

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
Eur Urol
4
2024
Androgen, C, C-terminal collagen propeptide, CYP17, HSPC, Hormone-sensitive Prostate Cancer, Men, OS, Orteronel, Patients, androgen, bone alkaline phosphatase, castration-resistant prostate cancer, hormone-sensitive prostate cancer, men, metastatic prostate cancer, orteronel, patient, pyridinoline
Author NameAffiliation
Primo N LaraUniversity of California Davis Comprehensive Cancer Center
Maha HussainNorthwestern University
David I QuinnUSC Norris Comprehensive Cancer Center
Ian M Thompson
Neeraj AgarwalHuntsman Cancer Institute
  • 1 - 5

Datasets

Release 1.2